Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma (RMC)
Renal medullary carcinoma (RMC) is an extremely rare and aggressive [...]
Cabozantinib in combination with atezolizumab for advanced kidney cancer
This phase Ib study reports the results of a combination [...]
ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of non-clear cell kidney cancer
Non-clear cell RCC is about 20-25% of all RCC diagnoses [...]
ASCO 2021: Nivolumab plus cabozanitinib for non-clear cell kidney cancer
The cabozantinib/nivolumab combination has been shown to be effective at [...]
ASCO 2021: Cobozantinib plus nivolumab combination for non-clear cell kidney cancer
The cabozantinib/nivolumab combination has been shown to be effective at [...]
ASCO GU 2021: Immunotherapy for untreated non-clear cell kidney cancer
Results of a retrospective study presented during the 2021 American [...]
ASCO GU 2021: Nivolumab plus ipilimumab combination in patients with non-clear cell kidney cancer
Data from the CheckMate-920 study on the safety and effectiveness [...]
Pembrolizumab as first-line treatment for kidney cancer
The recent phase II KEYNOTE-427 study investigated the efficacy and [...]
Top stories from 2020 for kidney cancer
Dr Sumanta (Monty) Pal, Clinical Professor and Co-Director of the [...]
2020 top stories in kidney cancer
This article summarises the key breakthroughs in the treatment of [...]
